Speculatively Bullish Options Activity in Mylan (MYL) -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Mylan (MYL) & Biocon Ltd. Presented New Clinical Data on Insulin Glargine Program at ADA Meetings
June 12, 2017 5:55 AM EDTMylan N.V. (NASDAQ: MYL) and Biocon Ltd. today announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessions in San Diego. The studies confirmed the efficacy, safety and immunogenicity of MYL-1501D, insulin glargine, in comparison to Lantus® in patients with Type 1 and Type 2 diabetes. Data demonstrating pharmacokinetic and pharmacodynamic equivalence also was presented.
Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as... More
Small is lucrative for Wachtell, corporate America's legal defense force
June 8, 2017 4:45 AM EDTBy Greg Roumeliotis
NEW YORK (Reuters) - Every Tuesday, partners and associates at Wachtell, Lipton, Rosen & Katz gather for a communal lunch in the dining room of the law firm's Manhattan offices.
Food ordered from top New York restaurants is served, but the real attraction is Martin Lipton, one of the firm's co-founders and corporate America's most famous consigliere.
The father of the 'poison pill' a key defense strategy used against hostile takeovers Lipton has helped build the firm into the most lucrative legal outfit in the world, a go-to shop for companies seeking to seal... More
Mylan defends chairman to ISS ahead of June 22 investor vote
June 7, 2017 10:42 AM EDT(Reuters) - Mylan NV (NASDAQ: MYL) defended Chairman Robert Coury's role to ISS this week as the influential proxy firm prepares to advise shareholders on how they should vote on the re-election of Coury and other directors, according to a letter the drugmaker released on Wednesday.
New York City and State pension funds and the California Teachers' Retirement System are urging shareholders to vote on June 22 against Coury and five other directors. The funds cite the board's poor oversight of Coury's high pay package, investigations into how much it charged the government and... More
